HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients

Area of Science:

• Hepatology
• Virology
• Clinical Immunology

Background:

• Serum hepatitis B surface antigen (HBsAg) quantification (qHBsAg) is increasingly utilized in managing Hepatitis B virus (HBV) infection.
• HBsAg titers show a negative correlation with liver fibrosis in patients who are hepatitis B e antigen-positive (HBeAg(+)).

Purpose of the Study:

• To explore the clinical utility of qHBsAg in classifying patients during HBV natural history.
• To assess the role of qHBsAg in monitoring antiviral therapy for HBV.
• To evaluate qHBsAg for predicting treatment outcomes in HBV patients.

Main Methods:

• Analysis of HBsAg levels in relation to clinical parameters and treatment outcomes.
• Correlation of qHBsAg with liver fibrosis and viral load (HBV-DNA).
• Evaluation of the "week 12 stopping rule" based on qHBsAg during PEG-IFN therapy.

Main Results:

• In HBeAg(-) patients, HBsAg <1000 IU/ml and HBV-DNA <2000 IU/ml accurately identify inactive carriers.
• qHBsAg can identify patients unlikely to benefit from PEG-IFN therapy by week 12.
• The role of qHBsAg during nucleos(t)ide analogue treatment requires further clarification.

Conclusions:

• Serum HBsAg quantification is a valuable tool for classifying HBV patients and monitoring therapy.
• qHBsAg, in conjunction with HBV-DNA, assists in identifying inactive carriers and guiding treatment decisions.
• The "week 12 stopping rule" using qHBsAg shows promise for optimizing PEG-IFN therapy.